BOLT

Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

About Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Details

Daily high

$3.62

Daily low

$3.10

Price at open

52 Week High

$7.20

52 Week Low

$3.10

Market cap

6.9M

Dividend yield

Volume

Avg. volume

38,505

P/E ratio

-.22

Bolt Biotherapeutics, Inc. - Common Stock News

Details

Daily high

$3.62

Daily low

$3.10

Price at open

52 Week High

$7.20

52 Week Low

$3.10

Market cap

6.9M

Dividend yield

Volume

Avg. volume

38,505

P/E ratio

-.22